{"seq": 1, "variant": "treatment", "cmd": "pm collect personalized dosimetry Lu-PSMA radioligand therapy prostate cancer --max 150 -v", "exit_code": 0, "stdin_lines": 0, "stdout": "{\"pmid\": \"41506803\", \"title\": \"Nuclear Medicine and External Beam Radiation Therapy in Prostate Cancer: A Synergistic Approach.\", \"authors\": [\"Abdel-Wahab May\", \"Giammarile Francesco\"], \"journal\": \"Journal of nuclear medicine : official publication, Society of Nuclear Medicine\", \"year\": \"2026\", \"date\": \"2026-01-08\", \"abstract\": \"Radiopharmaceutical therapy (RPT) combined with external beam radiotherapy (EBRT) is emerging as a powerful approach in prostate cancer treatment. Historically rooted in early 89Sr trials, this combination leverages EBRT's precise targeting of visible tumors and RPT's ability to address microscopic or systemic disease. Clinical and preclinical evidence shows enhanced tumor control, improved pain relief, and improved quality of life with manageable toxicity. Advanced imaging-particularly prostate-specific membrane antigen (PSMA) PET-plays a pivotal role in precise disease mapping, patient selection, and therapeutic planning. PSMA-targeted RPT, including 177Lu-PSMA, expands the arsenal by delivering systemic radiation to PSMA-expressing cancer cells, with demonstrated overall survival benefits so far primarily in metastatic castration-resistant prostate cancer after androgen receptor pathway inhibitors and taxane therapies. Although practical challenges such as access, regulation, and dosimetry remain, ongoing trials are exploring concurrent and sequential strategies, including \u03b1-emitter radioligands, aiming to improve survival. As evidence accumulates and logistical barriers are addressed, combined RPT and EBRT is poised to become a standard, personalized treatment paradigm in prostate cancer care.\", \"doi\": \"10.2967/jnumed.125.271268\"}\n{\"pmid\": \"41203980\", \"title\": \"Intra-arterial Hepatic 177Lu-PSMA-Radioligand Therapy in Liver-Dominant Metastatic Castration-Resistant Prostate Cancer: A Case Series.\", \"authors\": [\"Fakkert Ruben K\", \"Braat Arthur J A T\", \"de Keizer Bart\", \"Bruijnen Rutger C G\", \"Bruijnen Cheryl P\", \"Poot Alex J\", \"Smits Maarten L J\", \"Lam Marnix G E H\"], \"journal\": \"Cardiov", "stderr": "Searching PubMed: \"personalized dosimetry Lu-PSMA radioligand therapy prostate cancer\" (max 150)...\nFetching batch 1 (33 PMIDs)...\n", "elapsed_s": 2.096, "ts": 1771593260.39887}
{"seq": 2, "variant": "treatment", "cmd": "pm filter --year 2023- --has-abstract -v", "exit_code": 0, "stdin_lines": 33, "stdout": "{\"pmid\": \"41506803\", \"title\": \"Nuclear Medicine and External Beam Radiation Therapy in Prostate Cancer: A Synergistic Approach.\", \"authors\": [\"Abdel-Wahab May\", \"Giammarile Francesco\"], \"journal\": \"Journal of nuclear medicine : official publication, Society of Nuclear Medicine\", \"year\": \"2026\", \"date\": \"2026-01-08\", \"abstract\": \"Radiopharmaceutical therapy (RPT) combined with external beam radiotherapy (EBRT) is emerging as a powerful approach in prostate cancer treatment. Historically rooted in early 89Sr trials, this combination leverages EBRT's precise targeting of visible tumors and RPT's ability to address microscopic or systemic disease. Clinical and preclinical evidence shows enhanced tumor control, improved pain relief, and improved quality of life with manageable toxicity. Advanced imaging-particularly prostate-specific membrane antigen (PSMA) PET-plays a pivotal role in precise disease mapping, patient selection, and therapeutic planning. PSMA-targeted RPT, including 177Lu-PSMA, expands the arsenal by delivering systemic radiation to PSMA-expressing cancer cells, with demonstrated overall survival benefits so far primarily in metastatic castration-resistant prostate cancer after androgen receptor pathway inhibitors and taxane therapies. Although practical challenges such as access, regulation, and dosimetry remain, ongoing trials are exploring concurrent and sequential strategies, including \u03b1-emitter radioligands, aiming to improve survival. As evidence accumulates and logistical barriers are addressed, combined RPT and EBRT is poised to become a standard, personalized treatment paradigm in prostate cancer care.\", \"doi\": \"10.2967/jnumed.125.271268\"}\n{\"pmid\": \"41203980\", \"title\": \"Intra-arterial Hepatic 177Lu-PSMA-Radioligand Therapy in Liver-Dominant Metastatic Castration-Resistant Prostate Cancer: A Case Series.\", \"authors\": [\"Fakkert Ruben K\", \"Braat Arthur J A T\", \"de Keizer Bart\", \"Bruijnen Rutger C G\", \"Bruijnen Cheryl P\", \"Poot Alex J\", \"Smits Maarten L J\", \"Lam Marnix G E H\"], \"journal\": \"Cardiov", "stderr": "17 articles passed filters\n", "elapsed_s": 0.361, "ts": 1771593282.637472}
{"seq": 3, "variant": "treatment", "cmd": "pm collect Lu-PSMA therapy prostate --max 200 -v", "exit_code": 0, "stdin_lines": 0, "stdout": "{\"pmid\": \"41717403\", \"title\": \"Genomic analysis in chemotherapy-na\u00efve prostate cancer prior to PSMA-targeted treatment.\", \"authors\": [\"Amghar Mariam\", \"Roscher Mareike\", \"Rausch Tobias\", \"\u00d6zg\u00fcr Hilal\", \"Bauder-W\u00fcst Ulrike\", \"Bruchertseifer Frank\", \"Morgenstern Alfred\", \"Bene\u0161 Vladim\u00edr\", \"Kratochwil Clemens\", \"Bene\u0161ov\u00e1-Sch\u00e4fer Martina\"], \"journal\": \"Frontiers in oncology\", \"year\": \"2026\", \"date\": \"2026\", \"abstract\": \"Chemotherapy is typically administered prior to consideration of tandem [225Ac]Ac-/[177Lu]Lu-PSMA-617 therapy in metastatic castration-resistant prostate cancer (mCRPC), making chemotherapy-na\u00efve patients who undergo tandem radionuclide treatment extremely rare. The genomic mechanisms dictating response and resistance to prostate-specific membrane antigen-radiopharmaceutical therapy (PSMA-RPT) in this setting remain unclear. While tandem therapy is expanding for aggressive disease, baseline genomic predictors of treatment outcomes are not well defined. We present rare chemotherapy-na\u00efve mCRPC cases treated with tandem PSMA-RPT and explore their molecular characteristics through plasma circulating tumor DNA (ctDNA). Blood samples were obtained from mCRPC patients receiving [225Ac]Ac-/[177Lu]Lu-PSMA-617 therapy. Cell-free DNA (cfDNA) was isolated and analyzed using ultra-low pass whole-genome sequencing (ULP-WGS). Genome-wide copy number alterations (CNAs) and tumor fraction (TFx) were inferred with the ichorCNA algorithm. This case series included five chemotherapy-na\u00efve patients-four with baseline characterization and one with longitudinal follow-up-providing a rare window into cfDNA CNAs at treatment initiation. Recurrent alterations included amplifications in chromosomes 1q, 7q, and 8q, and losses in 8p. Additional events such as 12q amplification and partial 9q gain were also observed. In Patient 5, serial cfDNA analysis demonstrated stable 8p loss and 8q gain across multiple treatment cycles, despite clinical progression, suggesting clonally persistent genomic drivers. Baseline cfDNA CNA profiling", "stderr": "Searching PubMed: \"Lu-PSMA therapy prostate\" (max 200)...\nFetching batch 1 (200 PMIDs)...\n", "elapsed_s": 2.344, "ts": 1771593292.256316}
{"seq": 4, "variant": "treatment", "cmd": "pm filter --year 2023- --has-abstract -v", "exit_code": 0, "stdin_lines": 200, "stdout": "{\"pmid\": \"41717403\", \"title\": \"Genomic analysis in chemotherapy-na\u00efve prostate cancer prior to PSMA-targeted treatment.\", \"authors\": [\"Amghar Mariam\", \"Roscher Mareike\", \"Rausch Tobias\", \"\u00d6zg\u00fcr Hilal\", \"Bauder-W\u00fcst Ulrike\", \"Bruchertseifer Frank\", \"Morgenstern Alfred\", \"Bene\u0161 Vladim\u00edr\", \"Kratochwil Clemens\", \"Bene\u0161ov\u00e1-Sch\u00e4fer Martina\"], \"journal\": \"Frontiers in oncology\", \"year\": \"2026\", \"date\": \"2026\", \"abstract\": \"Chemotherapy is typically administered prior to consideration of tandem [225Ac]Ac-/[177Lu]Lu-PSMA-617 therapy in metastatic castration-resistant prostate cancer (mCRPC), making chemotherapy-na\u00efve patients who undergo tandem radionuclide treatment extremely rare. The genomic mechanisms dictating response and resistance to prostate-specific membrane antigen-radiopharmaceutical therapy (PSMA-RPT) in this setting remain unclear. While tandem therapy is expanding for aggressive disease, baseline genomic predictors of treatment outcomes are not well defined. We present rare chemotherapy-na\u00efve mCRPC cases treated with tandem PSMA-RPT and explore their molecular characteristics through plasma circulating tumor DNA (ctDNA). Blood samples were obtained from mCRPC patients receiving [225Ac]Ac-/[177Lu]Lu-PSMA-617 therapy. Cell-free DNA (cfDNA) was isolated and analyzed using ultra-low pass whole-genome sequencing (ULP-WGS). Genome-wide copy number alterations (CNAs) and tumor fraction (TFx) were inferred with the ichorCNA algorithm. This case series included five chemotherapy-na\u00efve patients-four with baseline characterization and one with longitudinal follow-up-providing a rare window into cfDNA CNAs at treatment initiation. Recurrent alterations included amplifications in chromosomes 1q, 7q, and 8q, and losses in 8p. Additional events such as 12q amplification and partial 9q gain were also observed. In Patient 5, serial cfDNA analysis demonstrated stable 8p loss and 8q gain across multiple treatment cycles, despite clinical progression, suggesting clonally persistent genomic drivers. Baseline cfDNA CNA profiling", "stderr": "192 articles passed filters\n", "elapsed_s": 0.339, "ts": 1771593299.196165}
{"seq": 5, "variant": "treatment", "cmd": "pm collect dosimetry PSMA --max 150 -v", "exit_code": 0, "stdin_lines": 0, "stdout": "{\"pmid\": \"41713513\", \"title\": \"Continuous, Preclinical Activity Reconstruction in 177Lu-based Radiopharmaceutical Therapy Using a Sparse Uncollimated \u03b3-Sensor Network.\", \"authors\": [\"Lall Rahul\", \"Evans Michael\", \"Seo Youngho\", \"Niknejad Ali\", \"Anwar Mekhail\"], \"journal\": \"International journal of radiation oncology, biology, physics\", \"year\": \"2026\", \"date\": \"2026-02-17\", \"abstract\": \"177Lu-based radiopharmaceutical therapy (RPT) has shown increasing promise in the treatment of neuroendocrine and metastatic prostate cancer. Delivering optimal radiation dose to tumors while minimizing dose to organs-at-risk (OAR) remains an unmet need due to significant patient-to-patient heterogeneity in treatment response, necessitating multiple snapshots of the in vivo activity distribution. Towards this goal, here we present a high temporal-resolution activity reconstruction method demonstrated on preclinical prostate cancer models. Utilizing a priori knowledge of tumor locations from a pretherapy scan (e.g. PET/CT), we have developed a low-cost, sparse sensor network to reconstruct the real-time tumor and OAR activity in preclinical cancer models. The proposed system was successfully validated1 with a small custom phantom filled with [177Lu]Lu-PSMA-617 and (2) with 4 mice models, bearing varying numbers of tumors from two human prostate cancer cell lines (PC3-PIP, PC3-flu), to which [177Lu]Lu-PSMA-617 RPT was administered. Uncollimated \u03b3 counts using the developed network were acquired outside of the mouse at 10 minutes post-injection (m.p.i), 6 hours, 12 hours, 24 hours, and 48 hours post-injection (h.p.i). The developed system's total tumor activity and percent injected activity per milliliter of tissue (%IA/mL) reconstruction in tumors, kidneys, and bladders is highly linear with the total tumor activity (R2=0.991) and %IA/mL (R2=0.994) from state-of-art small-animal SPECT. Acquisition and reconstruction were performed at a 1-minute temporal resolution, greater than 30 times faster than conventional small-animal SPECT ima", "stderr": "Searching PubMed: \"dosimetry PSMA\" (max 150)...\nFetching batch 1 (150 PMIDs)...\n", "elapsed_s": 2.374, "ts": 1771593308.6342747}
{"seq": 6, "variant": "treatment", "cmd": "pm filter --year 2023- --has-abstract -v", "exit_code": 0, "stdin_lines": 149, "stdout": "{\"pmid\": \"41713513\", \"title\": \"Continuous, Preclinical Activity Reconstruction in 177Lu-based Radiopharmaceutical Therapy Using a Sparse Uncollimated \u03b3-Sensor Network.\", \"authors\": [\"Lall Rahul\", \"Evans Michael\", \"Seo Youngho\", \"Niknejad Ali\", \"Anwar Mekhail\"], \"journal\": \"International journal of radiation oncology, biology, physics\", \"year\": \"2026\", \"date\": \"2026-02-17\", \"abstract\": \"177Lu-based radiopharmaceutical therapy (RPT) has shown increasing promise in the treatment of neuroendocrine and metastatic prostate cancer. Delivering optimal radiation dose to tumors while minimizing dose to organs-at-risk (OAR) remains an unmet need due to significant patient-to-patient heterogeneity in treatment response, necessitating multiple snapshots of the in vivo activity distribution. Towards this goal, here we present a high temporal-resolution activity reconstruction method demonstrated on preclinical prostate cancer models. Utilizing a priori knowledge of tumor locations from a pretherapy scan (e.g. PET/CT), we have developed a low-cost, sparse sensor network to reconstruct the real-time tumor and OAR activity in preclinical cancer models. The proposed system was successfully validated1 with a small custom phantom filled with [177Lu]Lu-PSMA-617 and (2) with 4 mice models, bearing varying numbers of tumors from two human prostate cancer cell lines (PC3-PIP, PC3-flu), to which [177Lu]Lu-PSMA-617 RPT was administered. Uncollimated \u03b3 counts using the developed network were acquired outside of the mouse at 10 minutes post-injection (m.p.i), 6 hours, 12 hours, 24 hours, and 48 hours post-injection (h.p.i). The developed system's total tumor activity and percent injected activity per milliliter of tissue (%IA/mL) reconstruction in tumors, kidneys, and bladders is highly linear with the total tumor activity (R2=0.991) and %IA/mL (R2=0.994) from state-of-art small-animal SPECT. Acquisition and reconstruction were performed at a 1-minute temporal resolution, greater than 30 times faster than conventional small-animal SPECT ima", "stderr": "147 articles passed filters\n", "elapsed_s": 0.278, "ts": 1771593314.8022468}
